



July 15, 2022

Lumenis Be, Inc.  
Shlomit Segman  
Sr. Director, Regulatory Affairs  
1870 South Milestone Drive  
Salt Lake City, UT 84104

Re: K220877

Trade/Device Name: Selecta Duet LED, Digital Duet, Selecta LED Trio, Digital Trio Laser Systems  
Regulation Number: 21 CFR 886.4390  
Regulation Name: Ophthalmic Laser  
Regulatory Class: Class II  
Product Code: HQF  
Dated: March 14, 2022  
Received: March 25, 2022

Dear Shlomit Segman:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm> identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal

statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see <https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products>); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems>.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance>) and CDRH Learn (<https://www.fda.gov/training-and-continuing-education/cdrh-learn>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice>) for more information or contact DICE by email ([DICE@fda.hhs.gov](mailto:DICE@fda.hhs.gov)) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Anjana Jain, PhD  
Assistant Director  
DHT1A: Division of Ophthalmic Devices  
OHT1: Office of Ophthalmic, Anesthesia,  
Respiratory, ENT and Dental Devices  
Office of Product Evaluation and Quality  
Center for Devices and Radiological Health

Enclosure

## Indications for Use

510(k) Number (if known)

K220877

Device Name

Selecta Duet LED, Digital Duet, Selecta LED Trio, and Digital Trio Laser Systems

Indications for Use (Describe)

- Selecta Duet LED or Digital Duet: Photodisruption of ocular tissue using light energy emitted by a Nd:YAG laser, including dissection of the posterior capsule of the eye (posterior capsulotomy), iridotomy/ iridectomy, and selective laser trabeculoplasty.
- Selecta LED Trio or Digital Trio: Photodisruption of ocular tissue using light energy emitted by a Nd:YAG laser, including dissection of the posterior capsule of the eye (posterior capsulotomy), iridotomy/ iridectomy, selective laser trabeculoplasty, and retinal photocoagulation.

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

**CONTINUE ON A SEPARATE PAGE IF NEEDED.**

This section applies only to requirements of the Paperwork Reduction Act of 1995.

**\*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.\***

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services  
Food and Drug Administration  
Office of Chief Information Officer  
Paperwork Reduction Act (PRA) Staff  
[PRASStaff@fda.hhs.gov](mailto:PRASStaff@fda.hhs.gov)

*"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."*

**510(k) SUMMARY**

**PREPARATION DATE:** July 14, 2022

**APPLICANT:** Lumenis Be, Inc.  
1870 South Milestone Drive  
Salt Lake City, Utah 84104

**CONTACT PERSON:** Shlomit Segman, PhD  
Sr. Director, Regulatory Affairs  
Lumenis Be Ltd.  
Tel: +972-4-9599230 or +972-52-3667233

**DEVICE TRADE NAME:** Selecta Duet LED Laser System  
Digital Duet Laser System  
Selecta LED Trio Laser System  
Digital Trio Laser System

**CLASSIFICATION NAME:** Powered Laser Surgical Instrument

**DEVICE CLASSIFICATION:** Class II (21CFR§886.4390)

**PRODUCT CODE:** HQF

**PREDICATE DEVICE:** Selecta Duet and Trio Laser Systems  
Applicant: Lumenis, Inc.  
510(k) Number: K081704  
Classification Name: Powered Laser Surgical Instrument  
Device Classification: Class II (21CFR§878.4810)  
Product Code: GEX, HQF

The Selecta Duet and Trio Laser Systems have not been subject to a design related recall.

**DEVICE DESCRIPTION:**

The Selecta Duet LED and Digital Duet subject devices are each a fully integrated, high-performance diagnostic slit lamp and therapeutic laser delivery system. The diagnostic slit lamp is for examining the anterior segment of the eye, from the corneal epithelium to the posterior capsule. The integrated Nd:YAG Q-Switch laser module provides short pulses at the wavelength corresponding with the selected operating mode. Two modes are available:



- PD (YAG) mode: 1064 nm for photodisruption (PD) of ocular tissues in procedures such as posterior capsulotomy, iridotomy, and iridectomy, and
- SLT mode: 532 nm for Selective Laser Trabeculoplasty (SLT).

The Selecta LED Trio and Digital Trio subject devices are each created by connecting the Selecta LED Duet and Digital Duet, respectively, to a compatible, FDA-cleared, Lumenis continuous 532 nm wavelength photocoagulator laser, via the LaserLink S. When the user connects the Duet to the LaserLink S, the Duet-part acts only as a Slit Lamp since the integrated Duet-laser is disabled and the laser in the external photocoagulator takes over. This combination adds the ability to perform retinal photocoagulation, as well as other indications cleared for the continuous 532 nm wavelength photocoagulator laser. The user disconnects the Duet from the LaserLink S for the system to perform as a Duet.

#### **INTENDED USE/INDICATIONS FOR USE:**

- **Selecta Duet LED or Digital Duet:** Photodisruption of ocular tissue using light energy emitted by a Nd:YAG laser, including discission of the posterior capsule of the eye (posterior capsulotomy), iridotomy/ iridectomy, and selective laser trabeculoplasty.
- **Selecta LED Trio or Digital Trio:** Photodisruption of ocular tissue using light energy emitted by a Nd:YAG laser, including discission of the posterior capsule of the eye (posterior capsulotomy), iridotomy/ iridectomy, selective laser trabeculoplasty, and retinal photocoagulation.

#### **COMPARISON OF TECHNOLOGICAL CHARACTERISTICS:**

The subject laser systems are substantially equivalent to their respective predicate, predecessor K081704 laser systems. This is a catch-up 510(k) submission intended to update the Selecta Family of Laser Systems record at FDA with the changes that have been implemented in the subject devices. As such, the intended use/indications remain substantial equivalent to that for the cleared devices. Further, the implemented changes were primarily to be responsive to user feedback, upgrade to the latest user interface, or reflect a need to change a supplier or manufacturing contractor. The key changes are captured in the comparison table below.

*Table: Comparison of Technological Characteristics*

	<b>Cleared Devices</b> Selecta Duet and Trio Laser Systems (K081704)	<b>Subject Devices:</b> Selecta Duet LED, Digital Duet, LED Trio, and Digital Trio Laser Systems
<b>GENERAL</b>		
<b>Manufacturer</b>	Lumenis, Inc.	Lumenis Be, Inc.
<b>Regulation Number</b>	21CFR§878.4810	Same
<b>Regulation Name</b>	Powered Laser Surgical Instrument	Same
<b>Procodes</b>	GEX and HQF	Same
<b>Indications for Use</b>	<ul style="list-style-type: none"> <li>• <b>Selecta Duet:</b> Photodisruption of ocular tissue using light energy emitted by a Nd:YAG laser, including discission of the posterior capsule of the eye (posterior capsulotomy), and discission of pupillary membranes (pupillary membranectomy) in aphakic and pseudophakic patients, and iridotomy/iridectomy and selective laser trabeculoplasty.</li> <li>• <b>Selecta Trio:</b> Photodisruption of ocular tissue using light energy emitted by a Nd:YAG laser, including discission of the posterior capsule of the eye (posterior capsulotomy), and discission of pupillary membranes (pupillary membranectomy) in aphakic and pseudophakic patients, and iridotomy/iridectomy, retinal photocoagulation and selective laser trabeculoplasty.</li> </ul>	<ul style="list-style-type: none"> <li>• <b>Selecta Duet LED or Digital Duet:</b> Photodisruption of ocular tissue using light energy emitted by a Nd:YAG laser, including discission of the posterior capsule of the eye (posterior capsulotomy), iridotomy/iridectomy, and selective laser trabeculoplasty.</li> <li>• <b>Selecta LED Trio or Digital Trio:</b> Photodisruption of ocular tissue using light energy emitted by a Nd:YAG laser, including discission of the posterior capsule of the eye (posterior capsulotomy), iridotomy/iridectomy, retinal photocoagulation, and selective laser trabeculoplasty.</li> </ul>
<b>LASER SPECIFICATIONS</b>		
<b>Type</b>	Frequency-doubled/Q-switched Nd:YAG	Identical

	<b><u>Cleared Devices</u></b> Selecta Duet and Trio Laser Systems (K081704)	<b><u>Subject Devices:</u></b> Selecta Duet LED, Digital Duet, LED Trio, and Digital Trio Laser Systems
<b>Principal output – wavelength</b>	532 and 1064 nm	Identical
<b>Operating mode</b>	Frequency doubled/Fundamental, pulsed	Identical
<b>Pulse duration</b>	3 nanoseconds	Identical
<b>Energy (mJ)</b>	For 532 nm laser: 2 maximum For 1064 nm laser: 30 maximum	Identical
<b>Laser beam spot size</b>	For 532 nm laser: 400 µm at visual focal plane For 1064 nm laser: <8 µm full width half maximum	For 532 nm laser: 400 µm at visual focal plane For 1064 nm laser: <11 µm at visual focal plane, 8 µm full width half maximum calculated
<b>CDRH Rad. Health classification</b>	Class IIIb Lasers	Identical
<b>IEC 60825 classification</b>	Class 3B	Identical
<b>Laser Actuation</b>	Button or footswitch	Joystick button or Footswitch
<b>AIMING BEAM SPECIFICATIONS</b>		
<b>Type</b>	CW Diode laser	Identical
<b>Principal output</b>	635 nm wavelength	Identical
<b>CDRH Rad. Health classification</b>	Class II	Identical
<b>IEC 60825 classification</b>	Class 2	Identical
<b>SLIT LAMP</b>		
<b>Field of view</b>	11.3 mm diameter at 16X magnification	Identical
<b>Working distance</b>	70 mm	Identical

	<b><u>Cleared Devices</u></b> Selecta Duet and Trio Laser Systems (K081704)	<b><u>Subject Devices:</u></b> Selecta Duet LED, Digital Duet, LED Trio, and Digital Trio Laser Systems
<b>Slit rotation (°)</b>	-90 (horizontal) to + 90 (horizontal)	Identical
<b>Bulb</b>	Halogen, 30 W	Light Emitting Diodes, 5W
<b>COMPATIBLE 532 nm PHOTOCOAGULATOR LASER</b>		
	<ul style="list-style-type: none"> <li>Novus Spectra Laser System</li> </ul>	<ul style="list-style-type: none"> <li>Smart532 (K151109)</li> </ul>

The differences between the subject devices and their respective, predecessor, predicated devices do not raise different questions of safety and effectiveness and have been confirmed through testing.

**PERFORMANCE TESTING:**

Performance testing demonstrates that the subject devices are as safe and as effective as their respective, predicate, predecessor devices. These tests included:

- Evaluating the implemented changes using the same recognized standards that were used for the cleared devices:

<b>Standard Number</b>	<b>Standard Name</b>
<b>ANSI/AAMI ES60601-1:2005/ A2:2010</b>	Medical electrical equipment - Part 1: General requirements for basic safety and essential performance (IEC 60601-1:2005, MOD)
<b>IEC 60601-1-2 Edition 4.0:2014</b>	Medical electrical equipment - Part 1-2: General requirements for basic safety and essential performance - Collateral Standard: Electromagnetic disturbances - Requirements and tests
<b>IEC 60601-2-22 Ed. 3.1 b:2012</b>	Medical electrical equipment - Part 2-22: Particular requirements for basic safety and essential performance of surgical, cosmetic, therapeutic and diagnostic laser equipment
<b>IEC 60825-1:2014</b>	Safety of laser products - Part 1: Equipment classification and requirements
<b>ISO 15004-2</b>	Ophthalmic instruments — Fundamental requirements and test methods — Part 2: Light hazard protection
<b>ISO 14971 Third Edition 2019-12</b>	Medical devices - Application of risk management to medical devices



- Software/Bench Testing

Lumenis developed and verified the software in accordance with a major level of concern described in the FDA “Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices” and also per the IEC 62304:2006 and A1:2015 Medical Device Software - Software Life Cycle Processes standard.

The software/bench tests conducted on the modifications confirmed that they met their requirements.

**CONCLUSIONS:**

The provided performance testing supports a substantial equivalence determination. The subject devices are substantially equivalent to their respective, predicate, predecessor devices.